Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Streamlined Manufacturing Processes Deliver Strong Traction for Peptide Therapeutics Finds Frost & Sullivan - Therapeutic peptides are one of the most attractive options in recombinant medicine. Due to their low toxicity, high specificity and much lower molecular weight, it is easier to set up dosage plans for patients
Streamlined Manufacturing Processes Deliver Strong Traction for Peptide Therapeutics Finds Frost & Sullivan

 

PRZOOM - /newswire/ - Mountain View, CA, United States, 2011/03/09 - Therapeutic peptides are one of the most attractive options in recombinant medicine. Due to their low toxicity, high specificity and much lower molecular weight, it is easier to set up dosage plans for patients.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Although therapeutic peptides entered the market twenty years ago, they witnessed greater uptake during the past five or six years. Improvements in the manufacturing process and delivery systems triggered a revival of interest among consumers.

New analysis from Frost & Sullivan (technicalinsights.frost.com), Advances in Peptide Therapeutics, finds that in view of the recent revival, budgeting is the most crucial element for the R&D portfolio aspect of therapeutic peptides.

If you are interested in a virtual brochure on this study, please send an email to Sarah Saatzer, Corporate Communications, at sarah.saatzer[.]frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

"Emerging therapeutic areas for peptides such as anti-infectives, vaccines and CNS-targeting peptides can well set the stage for a new class of drugs in these areas, " notes Technical Insights senior research analyst Ipshita Chakraborty. "Several large pharmaceutical companies avidly fund detailed research in this field."

With peptide therapeutics poised for a boost with high funding inflows and collaboration between big pharmaceuticals, small biotechs, academia and contract manufacturing organizations, a major point of concern is effective portfolio design to take advantage of the therapeutic areas that have the highest market potential.

Portfolio management approaches differ among stakeholders. Small biotech companies focus on a single product or technology, while big pharmaceutical companies maintain a diverse portfolio by therapeutic area and focus on collaborations, mergers and acquisitions (M&A) and licensing. This creates a gap in stakeholder interconnections in this industry.

Cost-intensive manufacturing processes present barriers for small biotech companies that can synthesize peptides, but cannot get to the stage of market entry. Lastly, alternative de-risking approaches such as small molecules can be better for some diseases, therefore, restricting the entry of therapeutic peptides in that area.

Nevertheless, peptide therapeutics hold huge promise from a medical point of view for both patients and drug companies. Cost optimization in manufacturing and the development of non-invasive delivery technologies will go a long way in generating strong revenue growth for this sector and lead to better treatment outcomes for the patient.

"Efficient target discovery platforms and further research on peptide stability will greatly assist the manufacturing process, " concludes Chakraborty. "The advent of new manufacturing methods in solid-phase production will help scale down the production cost for peptides."

Advances in Peptide Therapeutics, a part of the Technical Insights subscription, provides an overview of the peptide therapeutics industry, the major stakeholders, the market drivers and challenges and a prioritized recommendation for R&D portfolio design. Further, this research service includes detailed technology analysis and industry trends evaluated following extensive interviews with market participants.

Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters, and research services.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit frost.com.

Advances in Peptide Therapeutics / D21C

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Streamlined Manufacturing Processes Deliver Strong Traction for Peptide Therapeutics Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan |
Contact: Sarah Saatzer 
210.477.8427 sarah.saatzer[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today